NCT01982682View on ClinicalTrials.gov

Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 4, 2013

Primary Completion Date

March 27, 2017

Study Completion Date

March 27, 2017

Conditions
Hematopoietic/Lymphoid Cancer
Interventions
RADIATION

Total-Body Irradiation (TBI)

Undergo TBI

BIOLOGICAL

Donor Lymphocyte Infusion (DLI)

Undergo DLI

DRUG

Cyclophosphamide

Given IV

PROCEDURE

Allogeneic hematopoietic stem cell transplantation (HSCT)

Undergo CD34+ selected allogeneic HSCT

DRUG

Mycophenolate mofetil

Given IV

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

All Listed Sponsors
lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT01982682 - Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor | Biotech Hunter | Biotech Hunter